Clinical Trial

Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation

Study acronym: STOPS 03
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Lubiprostone has established efficacy and a favorable safety profile in chronic constipation and irritable bowel syndrome with constipation (IBS-C). However, clinical data specifically supporting its use in slow-transit constipation (STC), a distinct subtype of chronic constipation, remains limited.
Protocol Amendment History 1 change
notable Trial sites expanded: 15 -> 20 locations 2026-08-06
Trial Details
NCT Number NCT07277907
Lead Sponsor Third Military Medical University
Conditions Slow Transit Constipation, Pharmacotherapy
Enrollment 346 participants
Start Date 2025-11-13
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05